Ozette Raises $26M in Series A Funding


Ozette Technologies, Inc.a Seattle, Wash.-based, tech-driven life science startup making a transformative leap in cell discovery and human immune system annotation, raised $26 million in Series A financing.

The round was led by Madrona Ventures with participation from Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture capital fund, Alexandria Venture Investments, OCV Partners and Duke University.

The company intends to use the funds to accelerate its growth and expand its capabilities on a multiomics platform, integrating single-cell proteomics and transcriptomics.

Led by Dr. Ali Ansary, CEO and Co-Founder, Ozette is a life science technology startup that is building a high-resolution smart single-cell immune monitoring platform and high-resolution dataset leveraging its new technologies of AI. AI-powered analysis, rooted in research initiated at the Fred Hutchinson Cancer Center and incubated at the Allen Institute for Artificial Intelligence (AI2), reveals reliable, high-resolution insights an order of magnitude faster than the reference manual analysis. Early partners include small and large biopharmaceutical companies developing therapies in oncology, autoimmune diseases and infectious diseases. Founded in late 2020, Ozette originated from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. A new state-of-the-art immunology lab under development will soon provide another asset and opportunity for partners to leverage the company’s technology, enabling automated and vertically integrated analysis for immune insights .




About Author

Comments are closed.